

## Dexmedetomidine versus Midazolam as an Anesthetic Adjuvant in Pediatric Cardiac Surgery: An Entropy Evaluation Study

Taman HI<sup>1</sup>\*, Eldereym AA<sup>2</sup>

<sup>1</sup> Lecturer, Department of Anesthesia and Surgical ICU, Department of cardiothoracic surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

<sup>2</sup> Department of Anaesthesia and critical care, Department of cardiothoracic surgery, Mansoura University, El-Gomhouria Street, Mansoura, Egypt.

**\*Corresponding Author:** Hani I. Taman, Lecturer, Department of Anesthesia and Surgical ICU, Department of cardiothoracic surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Tel: 07534268934

E-mail: hani\_taman@yahoo.com

**Received Date:** 02<sup>nd</sup> October 2019

**Accepted Date:** 01<sup>st</sup> November 2019

**Published Date:** 04<sup>th</sup> November 2019

**Citation:** Taman HI, Eldereym AA. Dexmedetomidine versus Midazolam as an Anesthetic Adjuvant in Pediatric Cardiac Surgery: An Entropy Evaluation Study. Enliven: J Anesthesiol Crit Care Med. 2019; 6(2): 009-016.

**Copyright:** ©2019 Hani I. Taman. This is an Open Access article published and distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

### Abstract

#### Introduction

Volatile anesthetics have dose-dependent myocardial depressant properties. Thus anesthetists should balance between myocardial stability and adequate depth of anesthesia. Certain adjuvant drugs like dexmedetomidine and midazolam can be used to obtain adequate depth of anesthesia with lower inhalational anesthetic requirement. Thus, avoiding of inhalational anesthetic drugs associated myocardial suppressing affect in such patients with already diseased heart.

#### Patients and Methods

Seventy children patients with corrective congenital open heart surgery were divided into two groups. One received dexmedetomidine (0.5 µg/Kg/hour) and the other received midazolam infusion (0.05 mg/Kg/hour) as adjuvant to sevoflurane based anesthesia monitored by entropy. End-tidal concentration of sevoflurane, heart rate, MAP, additional fentanyl boluses, extubation time, vomiting and emergence agitation were all recorded.

#### Results and Conclusion

Sevoflurane end tidal concentration, entropy readings, additional doses of fentanyl, heart rate, MAP, were higher in midazolam group when compared to dexmedetomidine group. Similarly extubation time was longer in midazolam group in comparison to dexmedetomidine group. Emergence agitation score was of no significant value between dexmedetomidine and midazolam group.

#### Conclusion

with continuous infusion of 0.5 µg/Kg/hour dexmedetomidine during sevoflurane based anesthesia, lower end tidal sevoflurane concentration and entropy readings were noticed in comparison to midazolam infusion. In addition, lowers intraoperative additional opioid requirements and shorter extubation time with more hypotension and bradycardia were observed with dexmedetomidine infusion when compared to midazolam infusion in pediatric congenital corrective cardiac surgery.

**Keywords:** End Tidal Concentration; Opioid Sparing; Adjuvant; Emergence Agitation; Hemodynamic Stability; Pain Assessment.

### Introduction

Patient safety during anesthetic management of pediatric cardiac surgery is fundamental. Almost all of anesthetic medications have dose-dependent myocardial depressant properties hence; there is no single universally-accepted agent for anesthetic management during cardiac surgery (1).

Generally, volatile anesthetics reduce systemic vascular resistance, slow the sinoatrial node discharge rate, increase conduc-

tion time and suppress myocardial contractility by changing of calcium ion flux (2,3). Sevoflurane is frequently used in pediatric cardiac surgery because of its non-pungency odor and rapid increases in alveolar concentration (4). However, with this agent cardiac output is not maintained with higher incidence of emergence agitation (5).

In order to reduce the required doses of anesthetic agents, adjuvant drugs can be used to obtain sufficient depth of anesthesia. Dexmedetomidine and midazolam are two commonly used

adjuvants. Dexmedetomidine is an alpha 2 adrenergic receptor agonists with sedative, analgesic, sympatholytic, and hemodynamic stabilizing properties (6,7). Midazolam is another sedative adjuvant, which promotes effective sedation, anxiolysis, and anterograde amnesia. Unfortunately, postoperative altered behavior and paradoxical hyperactive reactions may occur after its use (8).

To ensure adequate depth of anesthesia, entropy monitor is now used to assess the depth of anesthesia (9). Entropy indices is less interfered with electrocautery unit than BIS during intraoperative period (10).

We hypothesized that the addition of dexmedetomidine as an adjuvant to sevoflurane based anesthesia in pediatric congenital cardiac surgery decreases Sevoflurane requirement to obtain adequate depth of anesthesia with more hemodynamic stability and low emergence agitation and side effects when compared to midazolam.

This study aimed mainly at comparing the efficacy of Dexmedetomidine versus Midazolam as an adjuvant to inhalational anesthetics in pediatric cardiac surgery using entropy as a monitor of anesthesia depth. The second aim was to evaluate the effect of both drugs on hemodynamic stability, emergence agitation after sevoflurane use as well as any prominent associated side effects.

## Patients and Methods

Seventy patients aged between 3 and 5 years old, who were planned for elective corrective congenital open heart surgery using cardiopulmonary bypass under general anesthesia, were enrolled in this comparative study.

An informed written consent from all participants' guardians and acceptance of institutional review board were obtained. Patients with active respiratory tract infections, hepatic and renal insufficiency, previous or redo heart surgery, neurological dysfunction and endocarditis were excluded from the study.

Anesthesia was induced using sevoflurane 2%-3%, with loss of consciousness, intravenous line was inserted followed by injection of 5 µg/Kg fentanyl and rocuronium 1 mg/Kg to facilitate endotracheal intubation. After securing ETT, all patients were connected to a closed anesthetic breathing circuit and the fresh gas flow was set at 1 L/min. lungs were artificially ventilated using pressure controlled ventilation mode aiming at tidal volume 6–8ml/kg, inspiratory and expiratory ratio 1: 2 and end-tidal carbon dioxide concentrations at 35–40 mmHg.

Five leads electrocardiogram (ECG), pulse oximetry, side stream capnography, nasopharyngeal temperature, response entropy (RE) and state entropy (SE) were attached to each patient. A radial artery catheter (22 G) was inserted after doing modified Allen's test to monitor the arterial blood pressure and blood sampling during the entire procedure. Latter all patients were randomly allocated into two equal groups using closed envelop method:

A) Dexmedetomidine group: Patients received continuous infusion dexmedetomidine of 0.5 µg/Kg/hour throughout the op-

eration (11).

B) Midazolam group : Patients received continuous infusion of midazolam at 0.05 mg/Kg/hour throughout the operation (12).

Anesthesia was maintained in both groups with sevoflurane using Vapor 19.3 vaporizers (Drager, Lubeck, Germany). Vaporizer setting was increased slowly to obtain state and response entropy score values around 45-60 during surgery.

The commercially available Datex-Ohmeda module calculates entropy was used to monitor the depth of anesthesia. Two separate numerical values on a scale between 0 and 100 were recorded. The maximum value of the response entropy (RE) is 100, and the maximum value of the state entropy (SE) is 91. Numbers close to 100 mean that the patient is conscious, and numbers close to zero denote very 'deep' anesthesia. A clinically practical level of anesthesia is achieved when the value is between 45 and 60. Adequate level of anesthesia is obtained when the RE and SE values differs by (0-3). The increase in the difference between the RE and SE is an early sign of inadequate anesthesia (10, 13).

Intraoperatively, end-tidal concentration of sevoflurane, heart rate, MAP were recorded before starting the infusion of the tested drug, 10 minutes after drug infusion, skin incision, sternotomy, pericardiotomy, beginning and termination of CPB, closure of sternum and skin.

Additional fentanyl boluses, which were required to attenuate sympathetic stimulation throughout the surgery (when MAP or HR increased more than 25% of basal values), extubation time (elapsed time between cessation of anesthesia and tracheal extubation) and the incidence of postoperative vomiting were all recorded. Atropine and metraminol were used to treat any life threatening bradycardia or hypotension.

Emergence agitation was assessed at arrival to ITU and every 15 min for up to 2 hours. Emergence agitation was rated using a four-point scale modified by Watcha, et al (1=calm, 2=crying, but can be consoled, 3=crying and cannot be consoled, 4=agitated and thrashing around). Children with scores of 3 or 4 were considered to have an emergence agitation episode (14).

## Sample size Calculation

We were planning a study of a continuous response variable from independent control and experimental subjects with 1:1 ratio of two groups. In a previous study the response within each subject group was normally distributed with standard deviation 3.48. If the true difference in the experimental and control means is 3, we would need to study 29 experimental subjects and 29 control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with probability (power) 0.85. We had increased the number in each group up to 35 patients. The Type I error probability associated with this test of this null hypothesis was 0.05 (15).

## Statistical Analysis

Klomogorov-Smirnov test was used to test the data normality of distribution. t-test and Mann-Whitey U test were used for

analysis of normally and non-normally distributed continuous data. Chi-square or Fisher's exact tests were used for analysis of categorical data. The results were expressed as mean (SD), median and range or number and % of patients as appropriate. A P value < 0.05 was considered statistically significant. Statistical analysis was performed using statistical package for social sciences (SPSS) software (SPSS Inc., Chicago, USA), version 18.0.

## Tables and Results

No significant differences were found as regard age, gender weight, primary congenital defect, duration of surgery, CPB time and Cross clamp time when both groups were compared together (Table 1).

End tidal of sevoflurane concentrations required to obtain adequate depth of anesthesia were higher in midazolam group when compared to dexmedetomidine group after skin incision, sternotomy, pericardiotomy, start of CPB. The main reduction in end tidal sevoflurane concentration was 22.68 in dexmedetomidine group and 25.46 in midazolam group when compared to their basal values (Figure 1).

Both response and state entropy values were higher in midazolam group when compared to dexmedetomidine group after skin incision, sternotomy and pericardiotomy (Figure 2).

Additional doses of Fentanyl were higher in midazolam group when compared to dexmedetomidine group (Figure 3).

Only 7 cases were extubated after 1 hour in dexmedetomidine group and 5 cases in midazolam group. There was no significant difference between extubated cases in both groups as regard emergence agitation incidence (Table 2).

Time of extubation was longer in midazolam group  $4.4 \pm 0.59$  in comparison to dexmedetomidine group  $3.2 \pm 0.47$  (figure 4). Meanwhile the incidence of vomiting was insignificant between two groups 6 versus 7 cases respectively (Figure 5).


Both heart rate and mean arterial blood pressure were significantly higher in midazolam group when compared to dexmedetomidine group at skin incision, sternotomy and pericardiotomy time interval (Figure 6).

**Table 1. Demographic data of the studied groups. Data are expressed as number, %, mean  $\pm$  SD.**


	Group D (n=35)	Group M (n=35)
Age (months)	44.1 $\pm$ 7.5	46.2 $\pm$ 8.9
Weight (kg)	21.5 $\pm$ 3.7	22.1 $\pm$ 4.1
<b>Gender (n, %)</b>		
Male	19 (54.29%)	15 (42.56%)
Female	16 (45.71%)	20 (57.14%)
<b>Surgery (n, %)</b>		
ASD	10 (28.57%)	12 (34.28%)
VSD	11 (31.43%)	10 (25.57%)
SAM	9 (25.71%)	8 (22.59%)
CAVC	5 (16.67%)	5 (16.67%)
Duration of surgery (hrs)	4.3 $\pm$ 0.9	4.15 $\pm$ 1.11
CPB time (min)	56.1 $\pm$ 16.3	58.2 $\pm$ 15.6
Cross clamp time (min)	38.12 $\pm$ 11.5	41.2 $\pm$ 13.6

ASD: atrial septal defect, VSD: ventricular septal defect, SAM: sub aortic membrane, CAVC: Common atrio-ventricular canal, CPB: cardiopulmonary bypass.


**Figure 1. Average end tidal sevoflurane concentration in the studied groups Data are expressed in mean  $\pm$  SD.**



**Figure 2. Response and state entropy values in the studied groups Data are expressed in mean ± SD.**



**Figure 3. Additional doses of fentanyl the studied groups Data are expressed in mean ± SD.**




**Table 2. Emergence agitation incidence in the studied groups. Data are expressed as median and range.**

	Group D (n=7)	Group M (n=5)
After 60 minutes in ITU	1 (1 - 2)	1 (1 - 2)
After 75 minutes in ITU	1 (1 - 2)	2 (1 - 2)
After 90 minutes in ITU	2 (2 - 3)	2 (2 - 3)
After 105 minutes in ITU	2 (2 - 3)	2 (2 - 3)
After 120 minutes in ITU	2 (2 - 3)	2 (2 - 3)


ITU: Intensive Therapy Unit.

**Figure 4. Time of extubation in the studied groups Data are expressed in mean ± SD.**

**Figure 5. Incidence of vomiting in the studied groups Data are expressed in mean ± SD.**



**Figure 6. Intraoperative heart rate (beat/ minute) and mean arterial blood pressure of the studied groups Data are expressed in mean  $\pm$  SD.**



## Discussion

The main finding in the current study, was that sevoflurane anesthetic requirements are decreased with dexmedetomidine infusion compared to midazolam infusion. In addition, lower intraoperative opioid requirement, and shorter extubation time were noticed to be associated with dexmedetomidine when compared to midazolam infusion.

In the current study, low end tidal sevoflurane concentrations with lower entropy readings were recorded during anesthesia with dexmedetomidine infusion when compared to midazolam. The main reduction in end tidal sevoflurane concentration was 22.68% in dexmedetomidine group and 25.46% in midazolam group when compared to their basal values.

Dexmedetomidine activates presynaptic  $\alpha_2$ -adrenoceptors located in the locus ceruleus which represents the main brain noradrenergic nucleus. Locus ceruleus gives origin of different medullo-spinal noradrenergic tracts which are known as an important modulator of nociceptive neurotransmission where  $\alpha_2$ -adrenergic and opioidergic systems have common effector mechanisms (16).

Generally, activation of presynaptic  $\alpha_2$  adrenoceptor can reduce norepinephrine secretion with interruption of pain impulse progression. Postsynaptic central  $\alpha_2$  adrenoceptors activation suppresses the sympathetic activity.  $\alpha_2$ -adrenoceptor activation suppresses the neuronal firing, resulting in lowering blood pressure, heart rate, sedation, analgesia as well as decreasing gut motility, vascular and smooth muscle contraction according to its location in the CNS (16,17). Dexmedetomidine disinhibit the ventrolateral preoptic nucleus that releases inhibitory neurotransmitters as a part of the regulatory system of the circuitry natural sleep. Electroencephalogram studies concluded that dexmedetomidine sedative effects resemble stage 2 NREM sleep pattern (17). Based on the above facts, dexmedetomidine is an effective additive drug in general anesthesia by reducing the requirements of anesthetics and pain relieving medications to obtain an adequate anesthetic depth (18).

Regarding midazolam (an imidazobenzodiazepine derivative), its activation of GABA<sub>A</sub> receptor can produce sedation, convulsions termination, central muscle relaxation and anti-grade

amnesia, although it has query systemic analgesic effect (19).

In pediatric anesthesia, dexmedetomidine use was associated with reduction of other anesthetic requirements, inhibition of the sympathetic response to nociceptive stimuli and achievement of intraoperative hemodynamic stability as sedation during mechanical ventilation (20,21).

In previous studies, end-tidal sevoflurane was reduced by 27.3-33% with the use of dexmedetomidine 1  $\mu\text{g}/\text{kg}$  bolus followed by infusion of 0.6  $\mu\text{g}/\text{kg}/\text{h}$  (22). Similarly, in pediatric tonsillectomy patients, end-tidal sevoflurane decreased to 41.6% when dexmedetomidine 2  $\mu\text{g}/\text{kg}$  bolus was given followed by infusion of 0.7  $\mu\text{g}/\text{kg}/\text{h}$  when compared with fentanyl bolus (23). This reduction percentage in those studies are higher than in our study, this can be explained by low dose used in our study 0.5 compared to 0.6  $\mu\text{g}/\text{kg}/\text{h}$  and 0.7  $\mu\text{g}/\text{kg}/\text{h}$  used in previous researches. In a different study, when dexmedetomidine was infused at 0.1  $\mu\text{g}/\text{kg}/\text{h}$  in children undergoing minor surgery, surgical stimulation was attenuated and anesthetic requirements was reduced significantly (5,24).

Emergence agitation is a common phenomenon with sevoflurane anesthesia especially in young children. In spite of spontaneously terminated, it causes anxious recovery with possible patient harm, surgical site affection and patients dissatisfaction. This phenomenon is a multifactorial depending on patients' age and behavior, anesthetic medications and surgical complexity (25). Sevoflurane may irritate the central nervous system at certain points resulting in higher incidence of emergence agitation up to 70% (26).

In this study, we tried to evaluate the impact of using dexmedetomidine and midazolam on emergence agitation with sevoflurane anesthesia. In cardiac anesthesia, it is a routine to keep patient sedated and ventilated until ensuring postoperative hemodynamic, ventilation and hemostatic stability before extubation. This causes difficulty in assessing the impact of both drugs on emergence agitation as its peak incidence usually occurs within the early period after stoppage of sevoflurane anesthesia (14).

However it was reasonable to mention that some recent studies reported low possibility of emergence agitation after sevoflurane in children premedicated with dexmedetomidine either

as a bolus or continuous infusion (7,23). Also, Shukry et al noticed decreased symptoms of postoperative agitation in young patients premedicated with dexmedetomidine after sevoflurane without prolonged extubation or discharge time (27). In the same way, Jooste EH et al tried to find the optimal method for administration and dosing of dexmedetomidine for emergence agitation. He concluded that in contrast to our study, a rapid dexmedetomidine administration may be better than prolonged bolus infusion over 10 min (28).

For midazolam, Kulka et al., reported insignificant administration of 0.1 mg/kg of midazolam near the end of surgery for decreasing emergence agitation in children (29). Similarly, Kim et al., and Cohen et al., reported inefficacy of small midazolam dose given by end of procedures on emergence agitation phenomenon (30,31). In contrast, low dose of midazolam (0.03 mg/kg) was found to produce accepted suppression of emergence agitation with elongation according to Cho et al., (32).

In addition, intraoperative fentanyl doses required to achieve adequate analgesia and attenuation of sympathetic response to painful stimulations were lower in dexmedetomidine group when compared to midazolam group.

Dexmedetomidine produces its analgesic action through stimulation of Presynaptic  $\alpha_2$ -adrenoceptors in the locus ceruleus. These special types of receptors are responsible for regulation of sedation and pain relief in vivo (16,33).

Midazolam has also some analgesic properties. This is achieved by activating central benzodiazepine receptors ( $\gamma$ -amino butyric acid (GABA) receptor) in the central nervous system (34).

Despite intraoperative dexmedetomidine is known to decrease opioid requirements in children, the exact mechanism of dexmedetomidine opioid-sparing effects are still under investigations. Recently, a meta-analysis study reported that intraoperative dexmedetomidine can reduce postoperative pain scores and morphine consumption in adult (35). Dexmedetomidine could provide equivalent postoperative analgesic effect to intraoperative opioid use with superior postoperative analgesia in comparison to placebo group according to a new meta-analysis which has compared the effects of intraoperative dexmedetomidine, propofol and placebo on postoperative pain, analgesic doses, and untoward event (36).

In another study, administration of dexmedetomidine (2 and 4  $\mu\text{g kg}^{-1}$  I.V.) just after tube insertion decreases the postoperative required amount of opioid and increasing the intervals between opioid doses in comparison to administration of 1 or 2  $\mu\text{g kg}^{-1}$  fentanyl (37). Also dexmedetomidine was reported to lower intraoperative opioid use, has morphine-sparing effects and shorten hospital stay after tonsillectomy and adenoidectomy (38,39). Similar to our study, administration of dexmedetomidine (0.5  $\mu\text{gkg}^{-1}$  bolus and 0.5  $\mu\text{gkg}^{-1}$  h $^{-1}$  infusion) for children (less than 6 years old) undergoing cardiac surgery, is associated with attenuation of hemodynamic and neuroendocrine responses at incision, sternotomy, and post-bypass with reduction of opioid requirements (40).

According to Reves et al., study, which has investigated the antinociceptive effect of midazolam administration systemically on induced acute thermal and inflammatory pain in animal.

Midazolam appears to have a dual action, midazolam has analgesic effect by acting at spinal level and hyperalgesic effects by acting at supraspinal level (41).

Extubation time was shorter in dexmedetomidine group when compared to the midazolam group. This may be explained by either the shorter half-life of dexmedetomidine (2.1–3.1 hours) than that of midazolam (2.6 to 17.7 hours) or the lower additional fentanyl doses used in dexmedetomidine group in comparison to midazolam group (42,43).

Riker et al. compared the extubation time between dexmedetomidine and midazolam. He reported shorter extubation time in patients premedicated with dexmedetomidine compared with those receiving midazolam, which is in the same way with our finding (44). In the same way Dutta S, has compared the extubation times between dexmedetomidine, propofol and midazolam. He revealed equivalent extubation time of dexmedetomidine and propofol, besides both were shorter when compared with midazolam (45). Also, dexmedetomidine has been proposed to reduce the duration of mechanical ventilation with earlier extubation in comparison to midazolam (44).

According to the current study, dexmedetomidine has decreased both the heart rate and mean arterial pressure more significantly than during midazolam infusion at skin incision, sternotomy, pericardiotomy. The reduction in heart rate with dexmedetomidine could be attributed to triggering vagal neural activity, suppression of the sinus and atrioventricular node and reduction of catecholamines release (46,47).

Dexmedetomidine' induced mean arterial pressure reduction can be explained by the decline in heart rate, decrease of catecholamines release (43), inhibition of renin-angiotensin system, diuretic effect (48) and both its sedative and analgesic effects (49). Similar to this study, Vilo and his colleagues proved that dexmedetomidine can cause critical hypotension and bradycardia through blunting the sympathetic responses to stressful events (42).

In contrast, midazolam causes a remarkable increase in heart rate and minimal change in MAP, suggesting decreased parasympathetic activity and unchanged sympathetic activity or delayed recovery of parasympathetic activity after cessation of midazolam infusion (50). Galletly et al., discovered a vagolytic effect of midazolam (0.1 mg/kg) that increased the heart rate and mean arterial pressure (51).

Klamt et al. and Tokuhira et al investigated the antihypertensive effects of dexmedetomidine at two different infusion doses (1  $\mu\text{g/kg/h}$  and 0.4  $\mu\text{g/kg/h}$ ) and they found that the degree of systolic blood pressure reduction is remarkably dose dependent (52,53).

In contrary to the current study, Friesen et al. reported an elevation of the mean arterial blood pressure and systemic vascular resistance index after dexmedetomidine loading dose (1  $\mu\text{g/kg}$ , 0.75  $\mu\text{g/kg}$ , or 0.5  $\mu\text{g/kg}$ ) (54).

No significant difference was found between two groups as regard vomiting attacks. Postoperative nausea and vomiting (PONV) are common after sevoflurane. Although the exact mechanism is not well recognized, this may be explained by the

degradation of sevoflurane to formaldehyde or exposure to low levels of carbon monoxide (55). Both, dexmedetomidine and midazolam have antiemetic effect. Dexmedetomidine exerts its antiemetic effect through direct antiemetic of  $\alpha_2$  agonists, suppression of sympathetic tone. Meanwhile midazolam has direct action at the chemoreceptor trigger zone reducing dopamine synthesis and release (56,57).

This study has some limitations, it is known that the higher incidence of emergence agitation usually in the early postoperative period. With lower number of extubated cases within first hour in ITU, we were unable to assess the preventive effect of both drugs on the incidence of emergence agitation after sevoflurane anesthesia.

## Conclusion

With continuous infusion of 0.5  $\mu\text{g}/\text{Kg}/\text{hour}$  dexmedetomidine during sevoflurane based anesthesia, lower end tidal sevoflurane concentration and entropy readings were noticed in comparison to midazolam infusion. In addition, lowers intraoperative additional opioid requirements and shorter extubation time with more hypotension and bradycardia were observed with dexmedetomidine infusion when compared to midazolam infusion in pediatric congenital corrective cardiac surgery.

## References

- [1]. Alwardt CM, Redford D, Larson DF. General anesthesia in cardiac surgery: a review of drugs and practices. *J Extra Corpor Technol.* 2005 Jun;37(2):227.
- [2]. Stevens W, Cromwell T, Halsey M, Eger E, Shakespeare T, Bahlman S. The cardiovascular effects of a new inhalation anesthetic, Forane, in human volunteers at constant arterial carbon dioxide tension. *Anesthesiology.* 1971 Jul 1;35(1):8-15.
- [3]. Atlee JL, Bosnjak ZJ. Mechanisms for cardiac dysrhythmias during anesthesia. *Anesthesiology.* 1990 Feb 1;72(2):347-74.
- [4]. De Hert SG, Pieter W, Mertens E, Van Sommeren EW, De Blier IG, Stockman BA, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. *Anesthesiology.* 2002 Jul 1;97(1):42-51.
- [5]. Na Hs, Song Ia, Hwang Jw, Do Sh, Oh Ay. Emergence agitation in children undergoing adenotonsillectomy: a comparison of sevoflurane vs. sevoflurane-remifentanyl administration. *Acta Anaesthesiol Scand.* 2013 Jan;57(1):100-105.
- [6]. Shukry M, Miller JA. Update on dexmedetomidine: Use in nonintubated patients requiring sedation for surgical procedures. *Ther Clin Risk Manag.* 2010 Apr 15;6:111-132. PMID:20421911.
- [7]. Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anesthesia. *Br J Anaesth.* 2011 Sep;107(3):430-437. PMID:21685111.
- [8]. Dahmani S, Brasher C, Stany I, Golmard J, Skhiri A, Bruneau B, et al. Pre-medication with clonidine is superior to benzodiazepines. A meta-analysis of published studies. *Acta Anaesthesiol Scand.* 2010 Apr;54(4):397-402. PMID:20085541.
- [9]. Bein B. Entropy. *Best Pract Res Clin Anaesthesiol.* 2006 Mar;1;20(1):101-110.
- [10]. Grover VK, Bharti N. Measuring depth of anaesthesia-an overview on the currently available monitoring systems. *Indian Anaesthetists' Forum.* 2008 Oct;9:1-32.
- [11]. Ozcengiz D, Unlügenc H, Günes Y Karacaer F. The effect of dexmedetomidine on bispectral index monitoring in children. *Middle East J Anaesthesiol.* 2012 Feb;21(4):613-618.
- [12]. Pacifici GM. Clinical pharmacology of midazolam in neonates and children: effect of disease review. *Int J Pediatr Adolesc Med.* 2014;2014.
- [13]. Bonhomme V, Deflandre E, Hans P. Correlation and agreement between bispectral index and state entropy of the electroencephalogram during propofol anaesthesia. *Br J Anaesth.* 2006 Jul 7;97(3):340-46.
- [14]. Sato M, Shirakami G, Tazuke-Nishimura M, Matsuura S, Tanimoto K, Fukuda K. Effect of single-dose dexmedetomidine on emergence agitation and recovery profiles after sevoflurane anesthesia in pediatric ambu-

- latory surgery. *Anaesthesia.* 2010 Oct 1;24(5):675-682.
- [15]. Reshma M, Geetha R, Suresh G, Prathima T. Effect of dexmedetomidine bolus dose on isoflurane consumption in surgical patients under general anesthesia. *Anesth Essays Res.* 2016;10(3):649-654.
- [16]. Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic alpha-adrenergic pathways. *Diabetes.* 1978;27:554-562. PMID:648745.
- [17]. Huupponen E, Maksimov A, Lapinlampi P, Särkelä M, Saastamoinen A, Snäpär A, et al. Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep. *Acta Anaesthesiol Scand.* 2008 Feb;52(2):289-94.
- [18]. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. *Anesth Analg.* 2000 mar;90:699-705. PMID:10702460.
- [19]. Seddighi R, Egger CM, Rohrbach BW, Cox SK, Doherty TJ. The effect of midazolam on the end-tidal concentration of isoflurane necessary to prevent movement in dogs. *Vet Anaesth Analg.* 2011 may;38(3):195-202. PMID:21492384.
- [20]. Barton KP, Munoz R, Morell VO, Chrysostomou C. Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease. *Pediatr Crit Care Med.* 2008 Nov 1;9(6):612-617.
- [21]. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. *Pediatr Crit Care Med.* 2007 Mar 1;8(2):115-131.
- [22]. Nunes RR, Cavalcante SL. Influence of dexmedetomidine upon sevoflurane end-expiratory concentration: evaluation by bispectral index, suppression rate and electroencephalographic power spectral analysis. *Rev Bras Anestesiol.* 2002 Apr;52(2):133-145.
- [23]. Patel A, Davidson M, Tran MC, Quraishi H, Schoenberg C, Sant M, et al. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy. *Anesth Analg.* 2010 oct;111:1004-1010. PMID:20705788.
- [24]. Mason KP, Lerman J. Dexmedetomidine in children: current knowledge and future applications. *Anesth Analg.* 2011 Nov 1;113(5):1129-1142.
- [25]. Cravero J, Surgenor S, Whalen K. Emergence agitation in paediatric patients after sevoflurane anaesthesia and no surgery: a comparison with halothane. *Paediatr Anaesth.* 2000 Jul;10(4):419-24.
- [26]. Kim JM, Lee JH, Lee HJ, Koo BN. Comparison of emergence time in children undergoing minor surgery according to anesthetic: desflurane and sevoflurane. *Yonsei Med J.* 2013 May 1;54(3):732-738. PMID:23549823.
- [27]. Shukry M, Clyde MC, Kalarickal PL, Ramadhyani U. Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia. *Paediatr Anaesth.* 2005 Dec;15(12):1098-1104. PMID:16324031.
- [28]. Jooste EH, Muhly WT, Ibinson JW, Suresh T, Damian D, Phadke A, et al. Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization. *Anesth Analg.* 2010 Dec; 111(6): 1490-1496. PMID:21059743.
- [29]. Kulka PJ, Bressem M, Wiebalck A, Tryba M. Prevention of "post-sevoflurane delirium" with midazolam. *Anesthetist.* 2001 Jun;50(6):401-405. PMID:11458720.
- [30]. Kim YH, Yoon SZ, Lim HJ, Yoon SM. Prophylactic use of midazolam or propofol at the end of surgery may reduce the incidence of emergence agitation after sevoflurane anaesthesia. *Anaesthesia, pain & intensive care.* 2011 Sep;39(5):904-908.
- [31]. Cohen IT, Drewsen S, Hannallah RS. Propofol or midazolam do not reduce the incidence of emergence agitation associated with desflurane anaesthesia in children undergoing adenotonsillectomy. *Paediatr Anaesth.* 2002 Sep;12(7):604-9.
- [32]. Cho EJ, Yoon SZ, Cho JE, Lee HW. Comparison of the effects of 0.03 and 0.05 mg/kg midazolam with placebo on prevention of emergence agitation in children having strabismus surgery. *Anesthesiology.* 2014 Jun;120(6):1354-1361. PMID:24566243.
- [33]. Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, et al. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. *Anesth Analg.* 2008 Jun;106(6):1741-1748. PMID:18499604.
- [34]. Nishiyama T. Analgesic effects of systemic midazolam: comparison with intrathecal administration. *Canadian Anaesthetists' Society.* 2006 Oct 1;53(10):1004-1009.
- [35]. Schnabel A, Meyer-Frießem CH, Reichl SU, Zahn PK, Pogatzki-Zahn EM. Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trials. *Pain.* 2013 Jul;154(7):1140-1149. PMID:23706726.
- [36]. Schnabel A, Reichl SU, Poepping DM, Kranke P, Pogatzki- Zahn EM,

- Zahn PK. Efficacy and safety of intraoperative dexmedetomidine for acute postoperative pain in children: a meta-analysis of randomized controlled trials. *Paediatr Anaesth*. 2013 Feb;23(7):170–179. PMID:23043461.
- [37]. Pestieau SR1, Quezado ZM, Johnson YJ, Anderson JL, Cheng YI, McCarter RJ, et al. High-dose dexmedetomidine increases the opioid-free interval and decreases opioid requirement after tonsillectomy in children. *Can J Anaesth*. 2011 Jun;58(6):540-550. PMID:21461792.
- [38]. Olutoye OA, Glover CD, Diefenderfer JW, McGilberry M, Wyatt MM, Larrier DR, et al. The effect of intraoperative dexmedetomidine on postoperative analgesia and sedation in pediatric patients undergoing tonsillectomy and adenoidectomy. *Anesth Analg*. 2010 Aug;111(2):490–495. PMID:20610555.
- [39]. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. *Ann Pharmacother*. 2007 Feb;41(2):245-54.
- [40]. Mukhtar AM, Obayah EM, Hassona AM. The use of dexmedetomidine in pediatric cardiac surgery. *Anesth Analg*. 2006; 103: 52–56.
- [41]. Reves JD, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. *Anesthesiology*. 1985 Mar;62(3):310-324.
- [42]. Vilo S, Rautiainen P, Kaisti K, Aantaa R, Scheinin M, Manner T, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. *Br J Anaesth*. 2008;100(5):697–700. PMID:18378546.
- [43]. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam. A review of its pharmacological properties and therapeutic use. *Drugs*. 1984 Dec;28(6):519–543.
- [44]. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. *Jama*. 2009 Feb 4;301(5):489-499.
- [45]. Dutta S, Lal R, Karol MD, Cohen T, Ebert T. Influence of cardiac output on dexmedetomidine pharmacokinetics. *J Pharm Sci*. 2000 Apr;89(4):519-527.
- [46]. Hammer GB, Drover DR, Cao H, Jackson E, Williams GD, Ramamoorthy C, et al., The effects of dexmedetomidine on cardiac electrophysiology in children. *Anesth Analg*. 2008 Jan 1;106(1):79-83.
- [47]. Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G, et al., Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. *Ann Thorac Surg*. 1995;60:1709-1715.
- [48]. Villela NR, do Nascimento Júnior P, de Carvalho LR, Teixeira A. Effects of dexmedetomidine on renal system and on vasopressin plasma levels. Experimental study in dogs. *Rev Bras Anesthesiol*. 2005 Aug;55(4):429-440. PMID:19468631.
- [49]. Chrysostomou C, Di Filippo S, Manrique AM, Schmitt CG, Orr RA, Casta A, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. *Pediatr Crit Care Med*. 2006 Mar 1;7(2):126-31.
- [50]. Win NN, Fukayama H, Kohase H, Umino M. The Different Effects of Intravenous Propofol and Midazolam Sedation on Hemodynamic and Heart Rate Variability. *Anesth Analg* 2005 Jul;101(1):97–102. PMID:15976213.
- [51]. Galletly DC, Williams TB, Robinson BJ. Periodic cardiovascular and ventilatory activity during midazolam sedation. *Br J Anaesth*. 1996 Apr;76(4):503–507. PMID:8652320.
- [52]. Klamt JG, de Andrade Vicente WV, Garcia LV, Ferreira CA. Effects of dexmedetomidine fentanyl infusion on blood pressure and heart rate during cardiac surgery in children. *Anesthesiol Res Pract*. 2010;2010:1–7.
- [53]. Tokuhira N, Atagi K, Shimaoka H, Ujiro A, Otsuka Y, Ramsay M. Dexmedetomidine sedation for pediatric post Fontan procedure patients. *Pediatr Crit Care Med*. 2009 Mar;10(2):207-212. PMID:19188869.
- [54]. Friesen RH, Nichols CS, Twite MD, Cardwell KA, Pan Z, Pietra B, et al. The hemodynamic response to dexmedetomidine loading dose in children with and without pulmonary hypertension. *Anesth Analg*. 2013 Oct;117(4):953-959. PMID:23960035.
- [55]. Bedi A, Gallagher A, Fee JP, Murray JM. Postoperative nausea and vomiting following 8% sevoflurane anaesthesia. *Anaesthesia*. 2000 Jun;55(6):594-599.
- [56]. Smith I, Walley G, Bridgman S. Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery. *Eur J Anaesthesiol*. 2008 Oct; 25(10): 790-799. PMID:18544179.
- [57]. Florio TD. The use of midazolam for persistent postoperative nausea and vomiting. *Anaesth Intens Care*. 1992 Aug;20(3):383-386.